Pro-cancer signals are controlled by the expression and transcription of oncogenes. Transcription of DNA is dependent on the spatially and temporally coordinated interaction between transcriptional machinery (RNA polymerase II, transcription factors (TFs)) and transcriptional regulatory components (promoter elements, enhancers, silencers and locus control regions). Unique TFs have been identified in association with cancer. This review summarizes key oncogene-related TFs and organizes their pro-cancer activity according to the six hallmark functions (self sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis and metastatic spread) proposed as constituting the infrastructure of the malignant process.
Introduction
Recent developments in molecular biology and biomolecular technology show promise for dramatically altering current strategies of cancer treatment. Each cancer is a coopted complex adaptive network of dynamically evolving spatial-temporal biomolecular interactions. Multilevel functional complementation results from the interactions between spatial, temporal and/or process-dependent modules at each organizational level (genome-transcriptosome-proteome-metabolome) that crossreact producing a functional organizational hierarchy. 1 Work is now underway to integrate theoretical and experimental programs so as to map out and model, in qualitative and quantifiable terms, topological and dynamic properties of networks that control the behavior of cancer (cells). Development of high-throughput data collection techniques on both the genomic (for example, DNA and oligonucleotide microarray) and the proteomic (for example, LC/MS) level allows for simultaneous interrogation of the status of a cell's components at any given time and is contributing to our knowledge and understanding of the organization and, at a slower pace, the mechanics of cancer co-expression networks. Likewise, the emergence of GeneChip Mapping arrays (Affymetrix Inc., Santa Clara, CA) and ChIP-on-chip analysis 2 has produced a rapid expansion in our understanding of both the extent and phenotypic effects of transcription promoter polymorphisms. 3, 4 In one study, 50% of promoter sequence variants altering gene expression more than 1.5-fold were located within 100 bases 5 0 to the transcription start site. 4 Most regulation appears to occur at the level of transcription initiation, prompting attempts to establish topologies of transcriptional regulatory networks to allow for the analysis of regulatory links (transcription factor (TF)-gene) in addition to expression and co-expression changes of specific genes 5, 6 to delineate tumor versus normal tissue differences in a dynamic processing (rather than static) mode.
Transcription initiation is dependent on the spatially and temporally coordinated interaction between the transcriptional machinery (RNA polymerase II, general TFs, activators and co-activators) and the transcriptional regulatory element, which includes the docking-site core promoter, proximal promoter elements (usually near a CpG island) and distal promoter elements, enhancers that are functionally similar to proximal promoter elements, silencers (the binding sites for repressors), insulators that minimize the effect of neighboring genes and locus control regions, which regulate gene clusters. 7, 8 Dysregulation of transcriptional and consequent post-transcriptional processes contributing to both cancer initiation and persistence can occur by aberrant activation, repression and/or temporal/spatial dyscoordination as well as by structural changes including mutations (BRG1 and BRM), translocations (cMYC in Burkitt's lymphoma) and fusion (BCR-ABL). 8 Hanahan and Weinberg 9 have identified six hallmark functions that provide the necessary infrastructure for the malignant process. These include (1) self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory signals (antigrowth), (3) evasion of programmed cell death (apoptosis), (4) limitless replicative potential, (5) sustained angiogenesis and (6) tissue invasion and metastatic spread. This paper will provide a focused review of those TFs that, based on their associated signal transduction pathways, have been implicated in the carcinogenic process and, as such, have potential as therapeutic targets.
TF networks
To prepare this review, a list of 320 somatic oncogenes compiled by the Sanger Institute (http://www.sanger. ac.uk/genetics/CGP/Census/) was searched. The list was cross-referenced with the database at the National Center for Biotechnology Institute (http://www.ncbi.nlm.nih. gov/) to find unique TFs that are linked to cancer. Of the 63 original TFs identified, 19 have been culled that uniquely or differentially modulate gene expression in cancer with a potential for therapeutic manipulation. We also attempt to contextualize the TFs by classifying them on the basis of their hallmark functional activity as defined by Hanahan and Weinberg (Table 1) .
Self-sufficiency in growth signals
Unlike normal cells, cancer cells have the capacity for autochonous growth, thus providing an unregulated mechanism of proliferative stimulation free of the constraints imposed within normal tissues. 9 
NF-kB
The TF nuclear factor (NF)-kB is a family of five reticulendotheliosis (REL) proteins that can be broken into two groups: group 1 contains RELA (p65), c-REL and RELB and group II, NF-kB1 (p105) and NF-kB2 (p100). 10 The NF-kB protein influences gene transcription through a series of events that allows it to translocate to the nucleus. Inhibitor of NF-kB (IkBa) binds to NF-kB in the resting state, thereby sequestering the complex in the cytoplasm in an inactive conformation. Activation of the TF proceeds through a cascade of events consisting of the IkB kinase-mediated phosphorylation of IkBa, ubiquitination and consequent proteosomal degradation resulting in nuclear translocation of NF-kB.
11 NF-kB is constitutively active in several cancer types and has been associated with the regulation of cell proliferation, cell survival, invasion, metastasis and inhibition of apoptosis through the inhibitor of apoptosis (IAP) constellation and GADD45. 10 Inhibition of NF-kB signaling has been shown to retard tumor formation.
12 NF-kB downregulation inhibits the expression of vascular endothelial growth factor (VEGF) with a consequent reduction in vascular formation 12 and interacts with other TFs.
13,14

AP-1
The activator protein-1, AP-1, dimer is comprised of c-Jun, JunB, JunD, Fos, FRA-1 and FRA-2. The dimer combinations, as well as their specificity and stability, are determined by the composition of its leucine zipper region. Malignant cell proliferation is regulated by c-Jun through the repression of tumor suppressor genes, as well as through the induction of cyclin D1 transcription, 15 whereas JunB and JunD are more frequently negative regulators. c-Jun is unique in binding directly to a variant AP-1 site in the p53 promoter PF-1 site, characterized by a single base-pair exchange, to negatively regulate p53 transcription. 16 Notably, AP-1 inhibition has been shown 
TFs: their potential as targets for therapeutic approach to cancer C Mees et al to stymie breast cancer cell proliferation by suppressing mitogenic signals from peptide growth factors (insulinlike growth factor-1, epidermal growth factor, basic fibroblast growth factor and b-heregulin).
17
The different AP-1 subunits have different pro-cancer effects. In general, as noted, Jun and Fos proteins are associated with proliferation and inhibition of apoptosis, Fra-1 proteins enhance angiogenesis, and JunB and JunD can either stimulate or inhibit proliferation (generally, the latter). Modulation of AP-1 activity may be a novel approach to reducing malignant transformation; however, targeting to the malignant (as opposed to nonmalignant) tissue will be necessary 18 as AP-1 possesses both oncogenic and antioncogenic characteristics.
Steroid receptors
Cell proliferation in prostate cancer can be attributed to androgen receptor TF, which binds to its cognate response element in DNA. 19 Although chemical androgen ablation is associated with clinical response in over 80% of men with advanced prostate cancer, 20 the disease inevitably becomes hormone refractory and unresponsive to androgen suppression. In some tumor models, androgen receptors are either mutated or amplified resulting in enhanced ligand occupancy or activation by cross-talk with other growth factors. Disease progression ensues with eventually fatal results. 19, 20 Retinoic acid receptors (RARs) are members of a group of ligand-dependent TFs that also include steroids, thyroid hormone and vitamin D receptors. 21 RARs have several functions; however, the transcriptional activation of retinoic acid and DNA binding plays an important role in gene expression. 22 Experiments using human SCC71 squamous cell carcinoma lines showed that the cell proliferation was differentially dose-dependent on retinoic acid regulation. Low doses of retinoic acid increased proliferation of SCC71 by epidermal growth factor activation of ERK1, resulting in an increased expression of S-and G2-phase cyclins and cyclin-dependent kinases, increased Rb phosphorylation and increased E2F-1 DNA-binding activity. On the other hand, higher doses produced inhibition of ERK1 expression. 22 In other studies, increased expression of RARa is associated with cellular proliferation. 23 In an analysis involving advanced ovarian cancer patients conducted by Kaiser et al., 24 elevated expression of RARa was shown to be a poor predictor of survival. Elevated expression was also associated with poor prognosis in patients with oral squamous cell carcinoma, prostate and breast cancer. 23, 25, 26 Insensitivity to growth-inhibitory signals
The cell cycle can be temporarily held in a quiescent state (G0), until activation of the appropriate re-entry signal. Alternatively, in mature differentiating cells, proliferation is permanently halted by entry into the post-mitotic state. In malignancy, dysregulated TFs circumvent cell cycle checks and balances, thereby creating insensitivity to normal growth-modulating signals. 9 
Myc
Recent estimates suggest that c-Myc transcription regulates up to 15% of genes across different species. The myc TF family, which includes c-Myc, N-Myc and L-Myc, interacts through formation of heterodimeric complexes with proteins MAX and MAD as transcription regulators. 27 During cellular differentiation, there is a shift in binding from c-Myc/Max to Mad/Max; the latter competing for binding sites with the c-Myc/Max heterodimers. 28 Overexpression of c-Myc within the complex is associated with promoting cell cycle progression and inhibition of cell differentiation. 28, 29 N-Myc overexpression has been identified in several types of cancer (retinoblastoma, 30 small-cell lung cancer 31 and medulloblastoma 29 ) and has been shown to affect angiogenesis, in part, through the modulation of IL6. 32 Hatzi et al. 32 have recently demonstrated that N-Myc amplification enhances the malignant phenotype in neuroblastoma.
Brn-3b
Transcription factor Brn-3b belongs to the class IV POU domain family normally expressed in neurologic and reproductive tract tissues. Overexpression of Brn-3b causes increases in growth rate and proliferation. 33 Dennis et al. 33 suggest a role for Brn-3b in regulation of mammary cell growth. Non-malignant mammary cells or benign tumors do not express significant levels of Brn-3b. Budhram-Mahadeo et al. 34 found that increased mRNA and protein levels of Brn-3b repress BRCA-1 promoter activity and downregulate BRCA-1 expression. Modification of Brn-3b TF expression in human breast cancer cells correlates with heat shock protein-27 expression. 35 Heat shock protein-27 has been associated with growth, invasiveness and resistance to chemotherapeutic drugs. 35 
Evasion of programmed cell death
Programmed cell death, or apoptosis, constitutes one of the major mechanisms of cellular attrition. Apoptotic signaling is multifactorial and multiplex with both intrinsic and extrinsic components. Tumor development, growth and maintenance are critically related to the control of apoptotic function.
The p53 protein is made up of 393 amino acids that can be divided into four functional and structural domains. There is an acidic amino-terminal domain, a core DNAbinding domain, a tetramerization domain and a C-terminal regulatory domain. The N terminus positively regulates gene expression. 36 The p53 protein balances synthesis and repair, cell cycle arrest, senescence and apoptosis. Mutations of p53 occur in approximately 50% of all cancers and are generally associated with a worse prognosis as well as a higher 'resistance to treatment'. 37 TFs: their potential as targets for therapeutic approach to cancer C Mees et al Under normal conditions, p53 is activated by posttranslational modifications, such as acetylation and phosphorylation. This stabilizes and activates p53 in response to DNA damage resulting in either cell cycle arrest or apoptosis. 38 The exact response of p53 to DNA damage may be regulated by p300 in a model proposed by Iyer et al. 38 Low levels of p300 in colorectal cancer cells resulted in increased apoptosis in part because of increased p53 stability, which leads to reduced p21 transcription and increased PUMA activation. However, when p300 was not limiting, the proapoptotic pathway expressed minimal activation. The transient activation of p53 resulted in the transactivation of p21, which promoted cell cycle arrest. Several preclinical and clinical trials have now been performed validating the hypothesis that replacement of wild-type p53 function through gene replacement would promote anticancer activity and enhanced apoptotic activity. 39, 40 STAT Signal transducer and activator of transcription (STAT) is a family of seven proteins, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They are latent cytoplasmic TFs that are activated by cytokines, growth factor receptors and peptides. 18 These extracellular signals associate with and activate JAK (Janus kinases), which, in turn, catalyze the tyrosine phosphorylation of the receptor-bound STAT, which, following dimerization, translocates to the nucleus to regulate gene expression. With regard to their role in malignancy, STAT3 and STAT5 have been shown to promote cell proliferation and prevent apoptosis in different cell types. 41 STAT3 activates IL-6-responsive genes 42 and is constitutively activated in IL-6-dependent multiple myeloma cell lines as well as in bone marrow mononuclear cells from multiple myeloma patients. Furthermore, it has been shown that apoptotic resistance is a result of constitutive activation in hematological malignancies, inhibiting STAT3-promoted apoptosis in leukemic large granular lymphocytes. 43 Niu et al. 44 have also demonstrated a mechanism whereby STAT3 inhibits p53 gene transcription. Blocking STAT3 in this scenario could provide a novel approach to reestablishing p53 expression in dysregulated cells.
STAT3 also mediates angiogenesis following epidermal growth factor receptor activation and STAT3-Src kinase, which in turn induce VEGF. Nui et al. 45 also showed a correlation between VEGF expression and STAT3 activity in several human cancer cell lines. In a study of structure-activity relationships of five cucurbitacin (Cuc) analogs, Sun et al. 46 have deconstructed the JAK/STAT3 relationship. A structure-activity relationship of Cuc Q demonstrated the ability to inhibit STAT3 and induce apoptosis, but not inhibit JAK2, Scr, AKT, ERK or JNK in nude mice xenografts. However, myeloma, breast cancer and prostate cell survival could be curtailed by targeting the JAK kinase family to block STAT3 activation. 47 Apoptosis of breast cancer cells could also be induced by blocking STAT3 with Src kinase inhibitors. 47 STATS 1 and 5 are activated in BCR-ABL fusionpositive CML patients. Constitutively activated STAT5 is also necessary for BCR-ABL-induced transformation. BCR-ABL tyrosine kinase inhibitors can block STAT5 signaling 48 with consequent growth arrest and induction of apoptosis. Tommi et al. 49 showed that STAT5 is activated in human prostate cancer cells. Inhibiting STAT5 leads to prostate cancer cell apoptosis.
FOX03a
FOX03a, formerly known as FKHRL-1, is a member of the Forkhead box protein group, the downregulation of which is associated with cell survival. Under normal conditions, following dephosphorylation, FOX03a translocates into the nucleus and triggers apoptosis through target genes (that is, Fas ligand gene). 50 AKT can inhibit the translocation of FOX03a to the nucleus through phosphorylation, thus inhibiting apoptosis and thereby enhancing cell survival. 51 FOX03a is a key regulator of estrogen receptor (ER)a gene transcription and has been linked to the expression of ERa in breast cancer cell lines. 50 Treatments with tamoxifen and estrogen withdrawal induce cell cycle arrest, which can be explained through the interaction of estrogen, ERa and Forkhead TFs. 52 
Limitless replicative potential
Eukaryotic cell replication results in the progressive shortening of the chromosomal telomere region. With the exception of stem cells and germ cells, normal cells lack telomerase resulting in a physical limit to the number of times a cell can undergo mitosis (generally 60-70 doublings: the Hayflick effect).
14 Telomerase is a reverse transcriptase that elongates the telomere region by adding a 'TTAGGG' repeat sequence at the 3 0 -end. 53 Tumor cells acquire the ability to produce and upregulate telomerase, thus achieving immortality. 9 
EWS/ETS
Ewing's sarcoma is characterized by the expression of a t(11;22)(q24;q12) translocation-induced EWS/ETS TF family member, most commonly EWS-FLI1. 54 This is a novel TF that targets telomerase. In cooperation with cyclic AMP-responsive element-binding (CREB) protein, EWS/ETS has been connected with the TERT, telomerase reverse transcriptase, and the transcription initiation complex. siRNA knockdown of EWS/FLI1 in Ewing's sarcoma cells reduces telomerase activity and TERT mRNA expression. 55 Furthermore, the same group confirmed telomerase stimulation by EWS/ETS fusion proteins in Ewing's sarcoma tumors by upregulation of TERT gene expression.
E2F
The TF E2F, also affected by RAR, is regulated through the phosphorylation of retinoblastoma susceptibility gene (RB1). The phosphorylation and dephosphorylation of pRB in late G 1 initiate the expression of genes necessary TFs: their potential as targets for therapeutic approach to cancer C Mees et al for the transition to the S phase of the cell cycle. pRB phosphorylation is primarily regulated by the cyclin D/CDK 4/6 complex and their interaction with the CDK inhibitor p16. The loss of RB1 or pRB expression is found in many tumors 56 including retinoblastoma, 57 bladder carcinoma 58 and malignant neuroendocrine lung carcinoma.
59 E2F-1 dysregulation has been associated with gastrointestinal and lymphatic tumors.
Sustained angiogenesis
Angiogenesis is a highly regulated process by which new blood vessels are, albeit dysfunctional, formed or coopted. 9 Tumor development and metastatic spread depend on an active angiogenic process to establish a supply of oxygen and nutrients, as well as a pathway for waste removal. 60 Hypoxia is a stress that modifies biological processes such as cell proliferation, angiogenesis, metabolism, apoptosis and immortalization, all of which are necessary for cancer cell viability. 61 
Hypoxia-inducible factor-1a
Hypoxia-inducible factor-1a responds to oxygen depletion in the cellular environment by forming a heterodimer with a second TF, aryl hydrocarbon receptor nuclear translocator, the hypoxia-inducible factor-1b subunit. Hypoxia-inducible factor-1a is thereby stabilized and gene transcription ensues through hypoxia response elements. This leads to the upregulation of several tumor progression-associated genes, one of which is VEGF, a known key angiogenic factor. 62 A study involving 92 ERnegative breast cancer patients suggested a relationship of aryl hydrocarbon receptor nuclear translocator splice variation with drug resistance and angiogenic induction. 62 
CREB
Multiple external stimuli as well as an intrinsic oxygensensing mechanism within the cell converge to activate CREB protein, a TF that promotes angiogenesis and resistance to apoptosis. 61 The hypoxia-response genes include the angiogenic gene VEGF 63 and the proapoptotic genes IAP2 64 and Bcl-2. 65 VEGF phosphorylates CREB at serine 133, which leads to DNA binding and transactivation. 63 The IAP2 gene promoter utilizes CREB-binding element to enhance activity under severe hypoxic conditions. 64 Using HCC transfected with CREB300/310, in which the two cysteine residues at positions 300 and 310 were converted to serine, resulting in enhanced CREB-binding efficacy and mediated gene expression, implanted mice responded with dramatically enhanced tumor growth. 61 When serine 133 was replaced with alanine (CREB300/310/133) producing a dominant negative, growth of implanted tumor cells was inhibited.
CREB along with activating transcription factor (ATF)-1 is upregulated in metastatic melanoma cells; overexpression gives rise to the metastatic phenotype through two mechanisms. CREB/ATF-1 can regulate the metalloproteinase MMP-2 and adhesion molecule MCAM/MUC18 gene to promote invasion. Using an inhibitory anti-ATF-1 single-chain antibody fragment (ScFv) to inhibit the transcriptional activity of ATF-1, Jean and Bar-Eli 66 showed that CREB was significantly reduced in melanoma cells and that subcutaneously transplanted tumors in nude mice underwent massive apoptosis in response to ScFv anti-ATF-1.
SP-1 SP-1, a member of the Sp Kru¨ppel-like family, is a ubiquitously expressed TF that controls many genes. Some genes have one promoter-binding site, whereas others have many. A single SP-1-binding site in a promoter can be viewed as a 'on/off' switch for gene expression. However, genes with multiple SP-1 promoter sites, such as oncogenes, are more likely to show modulated gene expression. Human pancreatic cancer cell lines and cancer tissue, 67 breast cancer cell lines and cancer tissue, 68 gastric carcinoma, 69 and thyroid carcinoma 70 have all shown overexpression or a higher binding activity of SP-1, which correlates with the upregulation of VEGF, 67 urokinase plasminogen activator and urokinase plasminogen activator receptor, 68 and epithelial growth factor receptor and epidermal growth factor receptor. 69, 71 Wei et al. 72 explored the use of COX-2 inhibition to reduce Sp1 DNA-binding and transcriptional activity. Suppression of Sp1 activity appeared to reduce VEGF expression in nude mice suppressing angiogenesis, tumor growth and metastatic spread. 72 
Tissue invasion and metastasis
Metastatic spread involves the migration of cancer cells from one place to another through the lymphatic system or bloodstream. This is the ultimate cause of death in 90% of patients with advanced cancer. 73 Transcriptional control of the metastatic process is complicated and involves several TFs including many of the previously mentioned TFs as well as the ETS family of TFs.
ETS
The ETS family has the ability to activate the transcription of matrix proteases urokinase-type plasminogen activator, collagenase I (MMP-12), stromelysin I (MMP-3) and gelatinase B (MMP-9). 74 Their dysregulated expression is associated with the metastatic potential of tumor cells. 75 The ETS family is divided into subfamilies based on the location of the 84 amino-acid sequence, or ETS domain, that binds to the core DNAbinding motif C/A GCA A/T. 76 It is most likely to promote the development of malignant phenotypes through translocation or deletion, as in Ewing's sarcoma and chronic myeloid leukemia. However, polyoma enhancer activator 3 (PEA3) (also known as E1AF and ETV4) and ETS-1 also play a role in tumor progression through metastatic potentiation and angiogenesis. 
PEA3
Although normal human cells show a weak expression of PEA3, PEA3 is overexpressed in several cancer types including breast 77, 78 and ovary. 78 Increased expression of PEA3 is associated with the overexpression of HER2/Neu in clinical breast cancer specimens. 77 Benz et al. 77 found neu-induced tumors to have differentially high levels of PEA3 mRNA in comparison with the surrounding mammary epithelium. Mammary tumor metastases to the lungs exhibit overexpression of PEA3, which is also indicative of overall worse survival. Co-expression of PEA3 and HER2 are associated with a significant increased rate of recurrence in women with breast cancer compared with HER2 overexpression alone. 79 Shephard et al., 80 using transgenic mouse models, showed that the downregulation of PEA3 could be a therapeutic target in the regulation of HER2/Neu and ultimately breast cancer.
Nitrous oxide (NO) plays a role in carcinogenesis, invasion and metastatic spread of colorectal cancer cells. NO affects b-catenin, which regulates PEA3, which activates the COX-2 gene. COX-2 overexpression expression is related to colorectal cancer and disease progression. Liu et al. 81 propose a sequential pathway for COX-2 activation: NO-b-catenin TCF/LEF-PEA3-COX-2. The inhibition of COX-2 also suppresses SP-1, reducing angiogenesis by suppressing VEGF. Inhibiting this pathway through the downregulation of PEA3 may provide a novel therapeutic approach here as well. ETS-1 also regulates gene expression associated with metastatic potential by inducing angiogenic growth factors in endothelial cells. 76, 82 ETS-responsive elements are present in the promoter region of VEGF, which may explain a statistical correlation between ETS-1 and VEGF expression data in cancer cells. 74 Iwasaka et al. 82 performed a series of in vivo experiments using human umbilical vein endothelial cells, which showed that ETS-1 plays a role in angiogenesis, regulating proteases and the migration of endothelial cells.
Metastatic spread is directly linked to the glycolytic bonding of b1-6 Asn-linked oligosaccharides. 83 An antisense oligonucleotide for ETS-1 remodeled endothelial cell properties to inhibit the cell from migrating through basement membranes. 84 Lung metastases of mouse melanoma cells expressing high levels of N-acetylglucosaminyltransferase-V were suppressed by transfection of N-acetylglucosaminyltransferase-III, which replaces a b1-6 glycolytic bond with a b1-4 bond, further demonstrating the importance of oligosaccharides to metastatic spread. 85 ETS-1 shows pathophysiological significance with regard to malignancy potential. Its increased expression can be correlated with increased expression of N-acetylglucosaminyltransferase-V. 86 
Therapeutic vision
In silico modeling has revitalized and expanded our understanding of the carcinogenic process (initiation, promotion and maintenance) as an integrated, dynamic and robust multilevel hierarchical network. Malignancy is an evolved co-opted 'system' maintaining the robust characteristics of its ancestor normal tissue. The qualitative and quantitative dysregulation of 'normal tissue' molecular mechanisms resulting in the malignant process either establishes or supports its functional infrastructure that includes (1) self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory signals (antigrowth), (3) evasion of programmed cell death (apoptosis), (4) limitless replicative potential, (5) sustained angiogenesis and (6) tissue invasion and metastatic spread. 9, 67 The dysregulation of transcriptional regulatory structure and/or mechanisms is clearly an integral component in this process as shown by the number of TFs encoded by oncogenes and tumor suppressor genes ( Table 1) . As illustrated in Figure 1 , the potential regulatory steps for the expression of protein-coding genes amenable to therapeutic targeting form a complex network rather than a sequenced pathway from transcription initiation and elongation through mRNA processing, transport, translation and post-translational modifications. 87, 88 A key functional hub in this network appears to be located at the level of transcription initiation. 8 With exponentially accruing data from patient-derived fresh tissue with less dependence on xenograft, transgenic and cell-line-derived specimens and more sophisticated modeling approaches to analyze, cull, correlate and integrate static and dynamic data sets, 89 the potential for gene-based therapies capable of targeting key components of the transcription complex has raised expectations that, one day, we will be able to target individual patient tumorspecific and cancer-dependent components. 90 One approach being used at the Mary Crowley Cancer Research Centers employs individual patient-derived tumor and normal comparator tissue specimens for 2D-differential in-gel electrophoresis to determine differential tumor/normal tissue protein expression distributions followed by functional annotation and confirmation of mRNA overexpression (Affymetrix). Using current databases but prioritizing patient-derived databanks, 'cancer Genome Transcriptome Proteome (phosphoproteome) Metabolome Figure 1 The genome contains all the coded and non-coded information of the organism. Transcriptosomes switch on the specific genes coded through transcription to produce a proteome. The metabolome can be used to classify the proteome's phenotype, which influences subsequent gene expression through transcription. Table 1 lists TFs encoded by oncogenes and suppressor genes that we believe the literature supports as reasonable initial targets. Table 2 summarizes the preclinical data involving animal models in which these putative targets are explored. Targeting TFs as a therapeutic strategy in cancer patients raises three major concerns: selectivity, specificity and differential sensitivity. The global inhibition of a specific TF is likely to result in serious side effects. 90 This requirement for selective targeting necessitates optimization through cancer-directed delivery and cancer-specific effector activation (that is, using cancer-specific promoters, such as hTERT). 20 Transcription factors in the same family also have similar or shared motifs, or structures, but different functions (for example, STAT1 versus STAT3, c-jun versus jun B). This presents the second challenge. For treatments to be effective, the targeting moieties will have to be able to distinguish between TFs of the same family. Finally, quantitative rather than qualitative differences between cancer and normal tissues reflecting disruptions and divergences in temporal patterns and concentration gradients require attention to differential sensitivity. With the resurgence of systems biology applications, process dynamics, in addition to static analytics, is beginning to be addressed and applied in oncology. 89 The goal of an effective individualized therapeutic approach to cancer is beginning to come within our sight. Many factual, technical and conceptual hurdles remain and, as they are successfully passed, others seem to appear. Yet, progress is undeniable. TFs, the transcriptional machinery and the transcriptional regulatory element are novel targets for therapeutic attack. Our increased knowledge of transcription mechanics and the transcriptional regulatory network has led to a better understanding of the critical role these play in cancer. Recent developments in delivery vehicles and directed targeting (for example, liposomes, nanoparticles and aptamers) along with more accurate and potent effectors (that is, shRNA, siRNA, ribozymes, antisense oligonucleotides, small-molecule inhibitors and zinc finger proteins) are poised for translation into the clinic. TFs: their potential as targets for therapeutic approach to cancer C Mees et al
